Physician profile
Ida Bronfman
NPI 1396826814
$6,048.71
in general payments reported to CMS, 2019-2025
26 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $362 · 2021: $801 · 2022: $904 · 2023: $695 · 2024: $1,454 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,704.68 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $703.36 | 2021-2025 | Botox, Ubrelvy, Linzess |
| Novo Nordisk INC | $634.04 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $602.72 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $534.78 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $262.91 | 2019-2024 | Mounjaro |
| Pfizer INC. | $178.10 | 2024-2025 | |
| Glaxosmithkline, LLC. | $171.78 | 2023-2025 | Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $166.22 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $159.01 | 2020-2021 | |
| Astellas Pharma US INC | $153.28 | 2025 | Veozah |
| Amarin Pharma, INC. | $135.23 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $129.78 | 2024-2025 | Gemtesa |
| Horizon Therapeutics Plc | $123.63 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.95 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $55.28 | 2020-2025 | Zoryve |
| Vivus LLC | $44.23 | 2025 | Pancreaze |
| Novartis Pharmaceuticals Corporation | $37.55 | 2022 | |
| Axsome Therapeutics, INC. | $27.21 | 2025 | Symbravo |
| Daiichi Sankyo INC. | $22.98 | 2022 | |
| Galderma Laboratories, L.P. | $22.48 | 2023 | |
| Ardelyx, INC. | $19.43 | 2024 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $16.91 | 2019 | |
| Esperion Therapeutics, INC. | $16.44 | 2021 | |
| Exact Sciences Corporation | $15.83 | 2023 | Cologuard Collection Kit |
| Dermira, INC. | $13.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ida Bronfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.